This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
3/1/2021
and welcome to the Adverum Biotechnologies conference call. At this time, all participants are in the listen-only mode. Later, we will conduct a question-and-answer session after the prepared remarks. As a reminder, this conference call is being recorded. I would now like to hand the call over to Maisha Lacey, Vice President of Investor Relations and Corporate Communications of Adverum. Please go ahead.
Thank you, Anastasia, and welcome, everyone. Today, we issued a press release to share our development planning for ADBM 022 for our wet age-related macular degeneration, or wet AMD program, recent business progress, and our fourth quarter 2020 financial results. A copy of this announcement is available on the press releases page of the investor relations section of our corporate website, www.advirum.com. Please note that a replay of today's call will also be available on the events and presentation section of our website. Joining me today is Dr. Laurent Fisher, Chief Executive Officer, Leonie Patterson, President and Chief Financial Officer, Dr. Aaron Osborne, Chief Medical Officer, In addition, we are honored to have Dr. Arshad Kanani of the Sierra Eye Institute and an enroller in our Optic and Infinity clinical trials join us today. As a reminder, we will be making forward-looking statements, which include our product development plans, research activities, and anticipated upcoming milestones and operations. These statements are subject to risks and uncertainties, That may cause actual results to differ materially from those forecasted. A description of these risks can be found under the caption Risk Factors, described more fully in our quarterly report on Form 10-Q for the quarter ended September 30, 2020, and any subsequent filings with the FDC under the heading Risk Factors. And now I will turn the call over to our CEO, Dr. Laurent Fischer.
Thank you, Maisha. Good afternoon, everyone, and thank you for joining us today. I hope that everyone, including your family and friends, is staying safe and healthy. Before we begin, I'd like to personally thank Dr. Arshad Kanani for joining us today. We're very appreciative for his time, his deep expertise in the retina field, and his enthusiasm about the potential of our gene therapy product, ADDMO22, as a new and differentiated treatment option for patients with wet AMD and DME. Dr. Kanani is incredibly dedicated to his patients and to advancing new treatment options that have the potential to improve real-world outcomes. He's well known as an experienced investigator participating in many clinical trials. I also would like to thank all the patients, their families, and our investigators for continuing to enroll studies during this pandemic, which, as we know, is impacting this at-risk population of wet AMD patients we'll be talking about today. At Adverum, we're on a global mission to establish gene therapy as a one-time treatment that preserves patient sites for life. We are gene therapy pioneers, and we believe that we're at the forefront of disrupting the anti-VEGF market with our novel vector platform technology, AAD7 and 8. Our technology has the potential to dramatically alter the treatment paradigm for patients living with wet AMD and VME following a single in-office intravertebral injection, and we're keen to make it available to patients as efficiently and as soon as possible. Here's our agenda for today's virtual event. First, I will share some opening comments about our recent progress across the business. Next, Erin Osborne, our Chief Medical Officer, will provide details of our global Phase III program for ADDMO2-2. Then, Dr. Arshad Kanani will share a video of one of his patients living with wet ND who took part in our optic study. She will highlight her personal journey and the impact of ADDMO2-2 on her life. Then, I will have a fireside chat with Dr. Arshad Kanani. And finally, we'll take your questions. So I'm really excited to share today that we recently had a very collaborative meeting with the FDA and that based on the feedback from the agency on both the clinical development pathway and the CMC requirements for our pivotal program, we now have a clear path to targeted BLA submission for ADD-MO22 in wet AMD in 2024. As a reminder, we enrolled the first patient in OPTIC in late 2018 and have since made great progress advancing the development of our investigational gene therapy product. In uptake to date, we have observed that a single IVT injection of O2-2 demonstrates robust treatment responses with long-term durability and a favorable safety profile in well-ended patients who required frequent anti-AVGF injections to maintain their vision. Based on these positive results and the unmet need for a long-lasting treatment option, we proposed an accelerated timeline to the FDA to deliver ADDM022 to patients as quickly as we can. And now let me share with you the outcome of our FDA interaction. Previously, you may recall that we were planning to conduct first a Phase IIb study with a 2e and 6e11 doses, followed by a single Phase III study with one dose. With regards to dose selection, Given the impressive response and durability with 2E11 in this high treatment needs population and the predictable and minimal steroid eye drop prophylaxis, we have selected two doses that straddle the 2E11 to take into Phase III in newly diagnosed wet AMD patients. We're now moving directly to two global Phase III pivotal trials conducted in parallel that we plan to initiate in the fourth quarter of this year to support a BLA submission in 2024. We also plan to have interactions with international regulatory agencies in the coming months. These two phase three trials will be randomized mass studies, and we enroll a total of approximately 900 patients, comparing ADDM022 to Aflibrasan. We will evaluate two doses of ADDM022, one E11 and three 11, Importantly, we'll treat newly diagnosed patients in order to support a broad label in wet AMD. Finally, we plan to evaluate the potential for bilateral treatment with ADD-MO22 given the unmet medical need with up to one-third of patients developing bilateral disease. In a moment, Aaron will share additional details about our critical programs. Now let's revisit why we're focusing on developing a novel approach for the treatment of patients with wet AMD. We have conducted extensive market research, and we've had frequent discussion with retina specialists and patients, and our research has revealed that the largest unmet need for patients with wet AMD is for durable treatment that reduces the frequency of anti-VEGF injections for better efficacy, improved ease of administration, and better control of macular fluid. This is where ADD-MO2-2 fits in to addressing those patients' needs. If you look at the current treatment landscape, as well as treatments in development, we see that some approaches are extending the duration between treatment intervals by a magnitude of weeks. But ADD-MO2-2 is the only investigational non-surgical treatment option that has demonstrated long-term durability out to two years and is delivered as a single in-office IVT injection. and we plan to continue to follow patients in OPTIC out to five years. We believe that ADD-MO2-2 is uniquely positioned, unlike any other treatments on the market or in development, as an advanced gene therapy product with the potential to be a one-and-done approach for millions of people living with wet AMD globally. If we look at the clinical profile of ADD-MO2-2, including the recently presented data in GeoGenesis 2021, by Dr. Kanani, we strongly believe that ADD-MO22 has the potential to transform the treatment paradigm for patients living with wet AMD. Focusing on the 2E11 dose, you can see that two-thirds of the patients are injection-free for a follow-up of 68 weeks, and there's an 85% reduction in annualized anti-VEGF frequency. Importantly, This dose is a favorable safety profile and a predictable prophylactic steroid eyedrop regimen with no patients having any inflammation at the latest evaluation. With respect to the 611 dose, we continue to see remarkable durability and anatomical responses and a favorable safety profile. This dose is at the top of the response curve and is one that we continue to evaluate in DNE and plan to explore in additional indications of high unmet needs. We will share more about this in the future. Before I turn the call over to Aaron, I want to acknowledge that we continue to take precautions as a company to navigate the impact of COVID-19. We are optimistic to now have three approved vaccines, and we hope to return to normal soon. Despite the challenges during this pandemic, we were able to complete enrollment in our Infinity study in less than six months. and to invest in a new GMP commercial manufacturing facility in Durham, North Carolina. I would now like to turn the call over to Aaron. Aaron?
You're reading a preview of the ADVM Q4 2020 earnings call.
Free account.
